Market Trends of Global Cervical Cancer Diagnostics And Therapeutics Industry
The HPV Test Segment is Expected to Hold a Major Market Share During the Forecast Period
The Papanicolaou test is a cervical screening method that detects precancerous and cancerous processes in the cervix and colon. Abnormal findings are frequently followed by more sensitive diagnostic procedures and, if necessary, interventions aimed at preventing cervical cancer progression. An HPV test is recommended for women over 30 to detect the virus. The screening aids in detecting precancerous lesions caused by HPV, which can then be removed to prevent the development of invasive cancers.
The major factor driving the segment's growth includes the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the Globocan 2022, there were 662 thousand cases of cervical cancer reported across the world in 2022, and this number is projected to increase by 909 thousand by 2024. Therefore, the incidence of cervical cancer is found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes in the cervix years before the cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.
Moreover, increasing product launches in the country boosts the market. For instance, in May 2024, Roche secured FDA approval for its human papillomavirus (HPV) self-collection solution, marking a pioneering entry into the US market. HPV screening plays a crucial role in pinpointing women vulnerable to cervical cancer, enabling early detection and intervention, thereby mitigating the risk of cervical cancer development.
Thus, all the aforementioned factors, such as the growing burden of cervical cancer and the launches of HPV tests, are anticipated to drive the segment's growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is one of the largest cervical cancer diagnostics and therapeutics markets. The large market share is attributed to the high awareness of disease prevention among women in the region and to the many initiatives launched to prevent cervical cancer that have increased the reach of insurance coverage for cervical screening tests, especially for low-income women.
Cervical cancer is one of the leading causes of death among women in the United States. According to the American Cancer Society, based on data updated in January 2024 and the estimates for cervical cancer in the United States for 2022, about 13,820 new cases of invasive cervical cancer will be diagnosed. Since there are more cases of cervical cancer in the United States, the market is likely to grow quickly over the next few years.
Additionally, favorable government policies in the United States are expected to drive the market during the forecast period. Updates from the Centers for Disease Control and Prevention in February 2022 reported that the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for screening for breast and cervical cancer has helped the market grow in the United States. Additionally, the month of January has been designated "Cervical Health Awareness Month" by the US Congress. The National Cervical Cancer Coalition (NCCC) and its many local chapters across the country raise awareness about cervical cancer, HPV disease, and the importance of early detection during January. While NCCC chapters host events throughout the year, Cervical Health Awareness Month is observed in January, and chapters work to raise awareness in their communities.
Moreover, growing product launches by the key market players support the market's growth. For instance, in July 2023, Merck revealed that in the Phase 3 KEYNOTE-A18 trial (ENGOT-cx11/GOG-3047), KEYTRUDA, its anti-PD-1 therapy, combined with external beam radiotherapy (EBRT) and concurrent chemotherapy, succeeded in meeting a primary endpoint: progression-free survival (PFS). This treatment was administered to newly diagnosed patients grappling with high-risk locally advanced cervical cancer.
Thus, all aforementioned factors, such as the growing burden of cervical cancer and product launches, are expected to grow in the coming years in North America.
